Home › Compare › RGDEF vs ABBV
RGDEF yields 400000.00% · ABBV yields 3.06%● Live data
📍 RGDEF pulled ahead of the other in Year 1
Combined, RGDEF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of RGDEF + ABBV for your $10,000?
RDX Technologies Corporation operates as an energy services and water treatment company in Canada and the United States. It operates through Environmental and Reclamation, Energy, Water, and Equipment Sales and Rentals segments. The Environmental and Reclamation segment engages in the acquisition and liquidation of distressed biofuel and water treatment facilities, including engineering consulting services and the disposal of excess real property and equipment. The Energy segment produces refined fuel. The Water segment offers waste water treatment and related services. The Equipment Sales and Rentals manufacture and sale of components and systems, comprising the sale and rental of complete waste water treatment systems. RDX Technologies Corporation manufactures waste treatment systems, including No Pump interceptor / grease trap system and Sans Tanker fluid transportation systems for water contaminants and the mining of contaminates. The company was formerly known as Ridgeline Energy Services Inc. and changed its name to RDX Technologies Corporation in August 2013. RDX Technologies Corporation is headquartered in Scottsdale, Arizona. On December 5, 2017, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Arizona.
Full RGDEF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.